This Article Full Text Full Text (PDF) All Versions of this Article: 112/10/1478    most recent CIRCULATIONAHA.105.548198v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ardern, C. I. Articles by Blair, S. N. Search for Related Content PubMed PubMed Citation Articles by Ardern, C. I. Articles by Blair, S. N. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Metabolic Syndrome Related Collections Epidemiology

(Circulation. 2005;112:1478-1485.)
© 2005 American Heart Association, Inc.

Preventive Cardiology

Revised Adult Treatment Panel III Guidelines and Cardiovascular Disease Mortality in Men Attending a Preventive Medical Clinic

Chris I. Ardern, MSc; Peter T. Katzmarzyk, PhD; Ian Janssen, PhD; Timothy S. Church, MD, MPH, PhD; Steven N. Blair, PED

From the School of Physical and Health Education (C.I.A., P.T.K., I.J.), Department of Community Health and Epidemiology (P.T.K., I.J.), Queen’s University, Kingston, Ontario, Canada; and The Cooper Institute (T.S.C., S.N.B.), Centers for Integrated Health Research, Dallas, Tex.

Correspondence to Peter T. Katzmarzyk, PhD, School of Physical and Health Education, 69 Union St, Queen’s University, Kingston, Ontario, Canada K7L 3N6. E-mail katzmarz{at}post.queensu.ca

Received March 9, 2005; revision received June 14, 2005; accepted June 17, 2005.

Background— National Cholesterol Education Program Adult Treatment Panel III guidelines recommend therapeutic lifestyle changes (TLC) and drug therapy to reduce cardiovascular disease (CVD) risk. These guidelines have been revised recently (ATP III-R); however, the risk of CVD mortality within each intervention window and the effects of cardiorespiratory fitness (CRF) and metabolic syndrome on CVD mortality within the framework of the guidelines are unknown.

Methods and Results— Risk factor and CRF data from 19 125 men (aged 20 to 79 years) who attended a preventive medical clinic between 1979 and 1995 were used. Mortality follow-up was completed until December 31, 1996. Participants were assigned to ATP III-R groups (LDL-C goal, TLC initiation, and drug consideration), and risk of CVD mortality was assessed by Cox proportional hazards regression. There were 179 CVD deaths over an average 10.2 years of follow-up. Compared with the LDL-C goal group, men in the TLC initiation and drug consideration groups had an elevated risk of CVD mortality (TLC initiation: HR=2.65, 95% CI 1.67 to 4.19; drug consideration: HR=6.44, 95% CI 4.49 to 9.25). Compared with LDL-C goal/fit, CVD mortality risk was higher in the LDL-C goal/unfit (4.8, 2.5 to 9.1), TLC initiation/fit (3.0, 1.7 to 5.3), TLC initiation/unfit (7.5, 3.7 to 15.2), drug consideration/fit (7.2, 4.6 to 11.4), and drug consideration/unfit (14.9, 9.1 to 24.4) groups. A similar gradient was observed for metabolic syndrome across intervention windows.

Conclusions— Men eligible for TLC or drug consideration under ATP III-R were at elevated risk of CVD mortality compared with men who met the LDL-C goal. Furthermore, men who were physically fit or who did not have the metabolic syndrome had a lower risk of CVD mortality.

Key Words: epidemiology • death, sudden • risk factors • follow-up studies • exercise

This article has been cited by other articles:

				Latest NCEP Guideline Criteria Predict CVD Mortality in Men Journal Watch Cardiology, October 14, 2005; 2005(1014): 6 - 6. [Full Text]